Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Nephrology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Blood Cancer Clinical Trials

A listing of Blood Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (91) clinical trials

Development of a Positive Psychology Intervention to Improve Mood and HRQoL in Patients Post-HSCT - Proof of Concept

Hematopoietic stem cell transplantation (HSCT) is a rigorous treatment for blood cancer patients that can be life-saving, but often causes psychological distress. The investigators hope that this study will help the research team to develop and implement a positive psychological intervention designed to help HSCT patients increase positive emotions such …

Phase N/A

Safety Study of SEA-CD40 in Cancer Patients

The study will be conducted in the following parts: Part A: Intravenous (IV) monotherapy dose-regimen finding for solid tumors -- Dose-escalation, and possible dose-interval modification to lengthen the treatment cycle, to define the IV SEA-CD40 monotherapy maximum tolerated dose (MTD) and/or the optimal biological dose (OBD) regimens in patients with …


Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older Medically Infirm or Frail Patients With Blood Diseases

PRIMARY OBJECTIVES: I. Compare in a randomized phase II study the effectiveness of supportive and palliative care, a clinical multi-modal program, or a combined approach versus usual care only (UCO) to determine the winning arm in improving health-related quality of life (HRQOL) (Day-90 Functional Assessment of Cancer Therapy-Bone Marrow Transplant …


NCI COVID-19 in Cancer Patients NCCAPS Study

PRIMARY OBJECTIVES: I. Characterize patient factors, such as pre-existing comorbidities, cancer type and treatment, and demographic factors, associated with short- and long-term outcomes of severe acute respiratory syndrome (SARS) coronavirus 2 (COVID-19), including severity and fatality, in cancer patients undergoing treatment. II. Describe cancer treatment modifications made in response to …

Phase N/A

Expressive Helping for Stem Cell Transplant Patients

Use of stem cell transplant (mostly for hematologic cancers) is expected to increase 5-fold by 2030, when the number of survivors will reach 500,000. This highly toxic treatment causes a range of acute physical and psychological symptoms, which then persist for years for up to 45% of patients. To address …


Expanded Access of Omidubicel for Allogeneic Transplantation in Patients With Hematological Malignancies

Successful blood and marrow transplantation (BMT) requires the infusion of a sufficient number of hematopoietic stem/progenitor cells (HSPCs), capable of both homing to the bone marrow and regenerating a full array of hematopoietic cell lineages with early and late repopulating ability in a timely fashion. Omidubicel is a stem/progenitor cell-based …


Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials

The need to 'personalize' cancer therapy has been recognized, with specific biomarkers which will be used to direct targeted agents only to those patients deemed most likely to respond. This "personalized cancer medicine" requires two critical steps: first, a comprehensive assessment of the biological characteristics of tumors from each individual, …

Phase N/A

Association Between Side Effects Occurrence and Concentrations of Ibrutinib and Idelalisib

Recently, European medicines agency approved ibrutinib and idelalisib in the treatment of Chronic Lymphocytic Leukemia (CLL) and two lymphomas: Follicular Lymphoma (FL) for ibrutinib and Mantle cell lymphoma (MCL) for idelalisib. Nevertheless, clinical trials for these two drugs were performed for only 300-350 patients and showed several side effects profiles, …

Phase N/A

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

This is a non-therapeutic, multi-center, long-term follow-up (LTFU) study of subjects who received a Fate Therapeutics NK cell product that has been modified by lentivirus-mediated genetically engineering. The period of follow-up is 15 years after the administration of the NK cell product. The study involves up to 15 years post-infusion …

Phase N/A

Evaluation Treatment and Training for Patients With Blood Disorders

This protocol is designed to allow the evaluation, follow up, and standard medical care of patients (and when appropriate, their stem cell donor) with bone marrow failure states, cytopenias, metastatic solid tumors, or hematologic malignancies not currently entered on an active NHLBI protocol or not being screened for an active …

Phase N/A